Sanofi CEO Finally Scores With $11.6B Buyout of Biogen's Spinoff Bioverativ Post author:Sam Post published:January 21, 2018 Post category:BioPharma The deal has Sanofi paying $105 per share in cash. Source: BioSpace You Might Also Like These 2 New Drugs Make Celgene an Even Bigger Biotech Powerhouse January 26, 2017 Could J&J’s Deal With Theravance Develop a Replacement for Remicade in IBD? February 20, 2018 Jazz Pharma Announces Offering Of $500 Million Of 1.50% Exchangeable Senior Notes Due 2024 August 17, 2017
Jazz Pharma Announces Offering Of $500 Million Of 1.50% Exchangeable Senior Notes Due 2024 August 17, 2017
